Target-Dose A. C. E. I. s Cut Kidney Failure in H. F. rEF. 03/12/26
Welcome to Cardiology Today – Recorded March 12, 2026. This episode summarizes 5 key cardiology studies on topics like advanced heart failure and implanted defibrillators. Key takeaway: Target-Dose A. C. E. I. s Cut Kidney Failure in H. F. rEF..
Article Links:
Article 1: Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device – a real-world, single center, observational study. (ESC heart failure)
Article 2: Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients. (ESC heart failure)
Article 3: Optimised murine HFpEF models for translational pre-clinical studies. (ESC heart failure)
Article 4: Are β-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-HFpEF Registry. (European journal of heart failure)
Article 5: Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF. (European journal of heart failure)
Full episode page: https://podcast.explainheart.com/podcast/target-dose-a-c-e-i-s-cut-kidney-failure-in-h-f-ref-03-12-26/
📚 Featured Articles
Article 1: Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device – a real-world, single center, observational study.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41812231
Summary: Left ventricular assist device therapy, particularly with the HeartMate 3, is an established treatment for advanced heart failure with reduced ejection fraction. This real-world study characterized the long-term outcomes of 176 patients receiving a HeartMate 3 device at a single center. The research provided specific findings regarding device survival and major adverse events over time in this patient population. These outcomes are crucial for understanding the durable support offered by the HeartMate 3 in clinical practice.
Article 2: Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41812230
Summary: Previous research established an association between metabolic syndrome and adverse heart failure outcomes in patients with implanted defibrillators or cardiac resynchronization therapy. This study investigated the specific role of metabolic syndrome and its components in predicting the risk of heart failure or death in non-obese patients with these devices. It included both obese and non-obese patients from a multicenter registry to analyze these predictive relationships. The findings clarified the impact of metabolic syndrome on cardiovascular outcomes in a previously understudied non-obese heart failure population.
Article 3: Optimised murine HFpEF models for translational pre-clinical studies.
Journal: ESC heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41812219
Summary: F. pEF models for translational pre-clinical studies. The study successfully optimized murine models for Heart Failure with preserved Ejection Fraction, or H. F. pEF, for improved translational pre-clinical studies. Researchers modified the two-hit model protocol by increasing L-NAME doses from 0.5 grams per liter to 1.75 grams per liter and extending protocol lengths from seven weeks to thirteen weeks. These changes reproduced H. F. pEF in both C57BL/6N and 6J mice, addressing previous limitations regarding sub-strain and sex. The refined three-hit model also included specific modifications, yielding more clinically representative models for H. F. pEF research.
Article 4: Are β-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-HFpEF Registry.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41810505
Summary: F. pEF Registry. The clinical effect of beta-blockers in patients with Heart Failure with preserved Ejection Fraction, or H. F. pEF, has been a subject of controversy. This study investigated how common comorbidities, specifically atrial fibrillation and ischemic heart disease, influence beta-blocker effects on H. F. pEF outcomes. Utilizing the PURSUIT-H. F. pEF registry, patients were divided into groups with or without these comorbidities. The research demonstrated how prognosis differed between beta-blocker users and non-users within these stratified patient populations, offering specific insights into treatment efficacy.
Article 5: Target-Dose Versus Below-Target-Dose ACE Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with HFrEF.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41797492
Summary: C. E. Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with H. F. rEF. This study found that target-dose angiotensin-converting enzyme inhibitors, or A. C. E. I. s, were associated with a lower risk of kidney failure compared to below-target-dose in U.S. Veterans with Heart Failure with reduced Ejection Fraction. While target-dose A. C. E. I. s and angiotensin receptor blockers are known to improve overall clinical outcomes in this population, their effect on kidney function, particularly kidney failure, has been less understood. The research demonstrated this benefit in a large cohort of 154945 Veterans, specifically addressing patients with advanced chronic kidney disease. These findings provide critical evidence supporting the use of target-dose A. C. E. I. s to mitigate kidney failure risk in Heart Failure with reduced Ejection Fraction.
📝 Transcript
Today’s date is March 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Long-term outcomes of patients implanted with a HeartMate 3 left ventricular assist device – a real-world, single center, observational study. Left ventricular assist device therapy, particularly with the HeartMate 3, is an established treatment for advanced heart failure with reduced ejection fraction. This real-world study characterized the long-term outcomes of 176 patients receiving a HeartMate 3 device at a single center. The research provided specific findings regarding device survival and major adverse events over time in this patient population. These outcomes are crucial for understanding the durable support offered by the HeartMate 3 in clinical practice.
Article number two. Effects of Metabolic Syndrome on Cardiovascular Outcomes in Non-Obese Heart Failure Patients. Previous research established an association between metabolic syndrome and adverse heart failure outcomes in patients with implanted defibrillators or cardiac resynchronization therapy. This study investigated the specific role of metabolic syndrome and its components in predicting the risk of heart failure or death in non-obese patients with these devices. It included both obese and non-obese patients from a multicenter registry to analyze these predictive relationships. The findings clarified the impact of metabolic syndrome on cardiovascular outcomes in a previously understudied non-obese heart failure population.
Article number three. Optimised murine H. F. pEF models for translational pre-clinical studies. The study successfully optimized murine models for Heart Failure with preserved Ejection Fraction, or H. F. pEF, for improved translational pre-clinical studies. Researchers modified the two-hit model protocol by increasing L-NAME doses from 0.5 grams per liter to 1.75 grams per liter and extending protocol lengths from seven weeks to thirteen weeks. These changes reproduced H. F. pEF in both C57BL/6N and 6J mice, addressing previous limitations regarding sub-strain and sex. The refined three-hit model also included specific modifications, yielding more clinically representative models for H. F. pEF research.
Article number four. Are β-Blockers Necessary for Patients with Heart Failure with Preserved Ejection Fraction? : PurSuit-H. F. pEF Registry. The clinical effect of beta-blockers in patients with Heart Failure with preserved Ejection Fraction, or H. F. pEF, has been a subject of controversy. This study investigated how common comorbidities, specifically atrial fibrillation and ischemic heart disease, influence beta-blocker effects on H. F. pEF outcomes. Utilizing the PURSUIT-H. F. pEF registry, patients were divided into groups with or without these comorbidities. The research demonstrated how prognosis differed between beta-blocker users and non-users within these stratified patient populations, offering specific insights into treatment efficacy.
Article number five. Target-Dose Versus Below-Target-Dose A. C. E. Inhibitors and Lower Risk of Kidney Failure in U.S. Veterans with H. F. rEF. This study found that target-dose angiotensin-converting enzyme inhibitors, or A. C. E. I. s, were associated with a lower risk of kidney failure compared to below-target-dose in U.S. Veterans with Heart Failure with reduced Ejection Fraction. While target-dose A. C. E. I. s and angiotensin receptor blockers are known to improve overall clinical outcomes in this population, their effect on kidney function, particularly kidney failure, has been less understood. The research demonstrated this benefit in a large cohort of 154945 Veterans, specifically addressing patients with advanced chronic kidney disease. These findings provide critical evidence supporting the use of target-dose A. C. E. I. s to mitigate kidney failure risk in Heart Failure with reduced Ejection Fraction.
Thank you for listening. Don’t forget to subscribe.
🔍 Keywords
advanced heart failure, implanted defibrillators, heart failure with reduced ejection fraction, murine model, atrial fibrillation, H. F. pEF, left ventricular assist device, kidney failure, A. C. E. I. s, angiotensin-converting enzyme inhibitors, heart failure, Heart Failure with reduced Ejection Fraction, cardiovascular outcomes, HeartMate 3, metabolic syndrome, non-obese, beta-blockers, prognosis, ischemic heart disease, Heart Failure with preserved Ejection Fraction, translational research, device survival, H. F. rEF, chronic kidney disease, cardiac resynchronization therapy, L-NAME.
ℹ️ About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • Follow